[A19-75] Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2019
Project no.:
A19-75
Commission:
Commission awarded on 29.08.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy
Negative effect in the outcome category of side effects does not call into question positive effects in morbidity and health-related quality of life; indication of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.